SUBMISSION INFORMATION
ISPOR is strongly committed to diversity. The Society’s Strategic Plan and core values embrace excellence through encouragement and acceptance of diverse ideas, cultures, and disciplines. Workshop submissions are encouraged from all stakeholders and are evaluated based on merit. ISPOR also aims to reflect the diversity of its membership in all endeavors and encourages consideration of diversity in abstract submissions. Diversity dimensions include (but not limited to) gender, career stage, ethnicity, race, education, sexual orientation, region/geographic location, physical disability, and religion. Additional information can be found at the Society’s Diversity Policy.
- ISPOR workshops are designed to share novel and innovative experiences in either the conduct of pharmacoeconomics and outcomes research studies or the interpretation and use of pharmacoeconomics outcomes information in health care policy development.
- An ISPOR workshop is similar to a one-hour short course with an audience participation element.
- Standard and advanced methods topics workshop submissions follow the same review process.
- Example of a breakout session proposal submission is available here (downloadable PDF).
SUBMISSION INSTRUCTIONS
Workshop submissions should be organized as follows:
STEP 1: GENERAL INFORMATION
- Acknowledgments: Submitting authors/submitters must agree to read and agree to ISPOR submission guidelines, ISPOR being an in-person only event, to incorporate audience interactive elements, and AI-Assisted Content Disclosure.
- Interactive Element: Provide all interactive elements you plan to utilize in your session.
- Title: Provide a title that accurately describes your breakout session. The title should be in title case, 225 character limit (including spaces). Examples:
- Fixing the Tower of Babel: Establishing a Common Metric for Patient-Reported Outcome Measures
- Optimal Allocation of Resources in Managing Medical Device Portfolios
- Adjusting for Between-Trial Differences in the Schedule of Assessment for Disease Progression in Immuno-oncology and Its Impact on Indirect Treatment Comparisons
- Submitter Email
- ISPOR Guidance on the Use of AI-Assisted Technologies in Content: ISPOR has implemented guidance on the use of artificial intelligence (AI) and AI-assisted technologies in submission to the Society’s conferences. Submitting authors/submitters are required to disclose the use of AI and AI-assisted technologies in their submitted abstract(s) and/or accepted materials. Standard word processing spelling and grammar checks do not need to be disclosed.
- Joint Clinical Assessment/Scientific Advice in the EU Related Content: Given the ongoing development of the Joint Clinical Assessment process in the EU and the accompanying methods guidance, we anticipate that this will be a highly relevant topic at ISPOR. Similarly, Joint Scientific Consultations constitute an integral part of the EU HTA regulation and provide an opportunity to discuss the development plan to generate evidence to meet the needs of both regulators and HTA bodies with regards to pharmaceuticals and medical devices. Sessions specifically relevant to either the process or methods involved in these areas, especially the more controversial aspects, will be highlighted in our program.
- RWE Related Content: All topics are welcome, but we also encourage the submission around the topic of real-world evidence.
- Indicate if Submitter or Authors are Member(s) of an ISPOR Chapter
- Level of Difficulty: Indicate if this session is Introductory, Intermediate, or Advanced in nature.
STEP 2: TAXONOMY/TOPIC
Select the taxonomy/topic that best describes your session.
Clinical Outcomes
Clinician Reported Outcomes
Comparative Effectiveness or Efficacy
Performance-based Outcomes
Clinician Outcomes Assessment
Relating Intermediate to Long-term Outcomes
Economic Evaluation
Cost/Cost of Illness/Resource Use Studies
Cost-comparison/effectiveness/utility/benefit Analysis
Budget Impact Analysis
Thresholds & Opportunity Cost
Trial-based economic evaluation
Work & Home Productivity - Indirect Costs
Value of Information
Novel & Social Elements of Value
Epidemiology & Public Health
Safety & Pharmacoepidemiology
Public Health
Prevalence, Incidence, & Disease Risk Factors
Disease Classification & Coding
Health Policy & Regulatory
Approval & Labeling
Pricing Policy & Schemes
Reimbursement & Access Policy
Insurance Systems & National Health Care
Public Spending & National Health Expenditures
Procurement Systems
Coverage with Evidence Development & Adaptive Pathways
Risk-sharing Approaches
Health Disparities & Equity
Health Service Delivery & Process of Care
Hospital and Clinical Practices
Prescribing Behavior
Pharmacist Interventions and Practices
Formulary Development
Telemedicine
Quality of Care Measurement
Disease Management
Treatment Patterns and Guidelines
Health Technology Assessment
Systems & Structure
Value Frameworks & Dossier Format
Decision & Deliberative Processes
Medical Technologies
Medical Devices
Digital Health
Diagnostics & Imaging
Implementation Science
Methodological & Statistical Research
Artificial Intelligence, Machine Learning, Predictive Analytics
Missing Data
Confounding, Selection Bias Correction, Causal Inference
Modeling & Simulation
PRO & Related Methods
Survey Methods
Organizational Practices
Academic & Educational
Industry
Ethical
Best Research Practices
Geographic & Regional
Patient-Centered Research
Adherence, Persistence, & Compliance
Stated Preference & Patient Satisfaction
Health State Utilities
Patient-reported Outcomes & Quality of Life Outcomes
Patient Behavior and Incentives
Patient Engagement
Instrument Development, Validation, & Translation
Real World Data & Information Systems
Data Protection, Integrity, & Quality Assurance
Health & Insurance Records Systems
Distributed Data & Research Networks
Reproducibility & Replicability
Study Approaches
Clinical Trials
Pragmatic Trials & Large Simple Trials
Prospective Observational Studies
Electronic Medical & Health Records
Registries
Administrative Claims Data
Surveys & Expert Panels
Decision Modeling & Simulation
Literature Review & Synthesis
Meta-analysis & Indirect Comparisons
STEP 3: LOCATION
What geographical region is this content about?
STEP 4: DISCUSSION LEADER/DISCUSSANTS
A workshop is comprised of a Discussion Leader and a minimum of 2 and a maximum of 3 discussants. All discussion leaders and discussants will be asked to provide any previous, relevant speaking/publication experience.
- Discussion Leaders maintain communication with discussants and ISPOR staff regarding the development and delivery of the session.
- Amongst the Discussion Leader and Discussants, a diversity of stakeholders, work environments and/or geographic locations is strongly encouraged to provide different perspectives on the topic.
- Only 2 discussants per organization is permitted
- Provide the names, degrees, work environment, affiliation, city, state, country, and email addresses for the discussants.
- You will be asked for full submitter information on this step as well. The submitter can be the same as an already listed participant.
STEP 5: PURPOSE/DESCRIPTION
- Length of Proposal (Purpose and Description): 300 words
- Purpose: Provide a clear definition of the workshop’s objective. (Ensure that the purpose(s) is achievable in 60 minutes.)
- Description: Provide a
clear description of the topic
including background information
& audience participation
- The audience interactive element is an important criterion to fulfill. Here are examples:
- Example 1: Each speaker will present a schematic of how patient preference data are included in their respective regulatory processes. The audience will participate in the evaluation exercise drawing on the pros versus cons of each arrangement to develop an ‘ideal’ process for using this data in healthcare decision making.
- Example 2: The workshop will use real-time polling to work through the examples and conclude with an audience discussion about the opportunities and challenges of using these different methods for portfolio selection.
- Example 3: The discussion leaders will conduct a real-time test of the validity of audience members’ preferences and help the audience evaluate the implications of such validity failures for regulatory decision making.
STEP 6: CONFIRMATION
Review your submission and complete the “Final Steps” acknowledgement form at the bottom. You must complete this final step and select “Conclude Submission,” otherwise your submission will be considered incomplete and not submitted for review. Please note: you will need to complete this step every time you update your submission.
CRITERIA FOR EVALUATION OF WORKSHOPS:
Overall, workshop acceptance is based on the quality of the proposal and the topic’s importance for inclusion and discussion in this conference’s scientific program. Standard and advanced methods topics workshop submissions follow the same review process.
Please consider the updated submission criteria when submitting your proposal:
Quality of content
- Educational value of the session
- Timeliness of the topic
- Applicability of content to HEOR practice or principles
- Effectiveness of incorporated active learning strategies
- The information/issue presented are novel or innovative
- Workshop proposals includes examples drawn from multiple sources
- Unbiased content that does not promote a product, service, or organization; abstracts deemed to be promotional will be excluded from consideration
Quality of proposal
- Plans for interactivity between the speakers and audience
- Proposal purpose/issue is clearly defined
- Issue panel proposals have more than one perspective identified
- The background information (included in the overview) is clear and concise
Quality of Speakers
- Expertise/experience of proposed speakers
- Proposed speakers represent diverse backgrounds (gender, geographic, institutional - refer to ISPOR Diversity policy) and perspectives (multiple organizations are represented)